Heron Therapeutics Inc vs ResMed Inc. — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 315× Heron Therapeutics Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | RMD | |
|---|---|---|
Market Cap | $91.46M | $28.81B |
Sector | Health | Health |
52-Week High | $1.96 | $293.73 |
52-Week Low | $0.39 | $182.82 |
Enterprise Value | $189.36M | $27.99B |
Dividend Yield | — | 1.21% |
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →